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A bs tr ac t
Background
Human prion diseases, although variable in clinicopathological phenotype, gener­
ally present as neurologic or neuropsychiatric conditions associated with rapid multi­
focal central nervous system degeneration that is usually dominated by dementia 
and cerebellar ataxia. Approximately 15% of cases of recognized prion disease are 
inherited and associated with coding mutations in the gene encoding prion protein 
(PRNP). The availability of genetic diagnosis has led to a progressive broadening of 
the recognized spectrum of disease.
Methods
We used longitudinal clinical assessments over a period of 20 years at one hospital 
combined with genealogical, neuropsychological, neurophysiological, neuroimag­
ing, pathological, molecular genetic, and biochemical studies, as well as studies of 
animal transmission, to characterize a novel prion disease in a large British kin­
dred. We studied 6 of 11 affected family members in detail, along with autopsy or 
biopsy samples obtained from 5 family members.
Results
We identified a PRNP Y163X truncation mutation and describe a distinct and consis­
tent phenotype of chronic diarrhea with autonomic failure and a length­dependent 
axonal, predominantly sensory, peripheral polyneuropathy with an onset in early 
adulthood. Cognitive decline and seizures occurred when the patients were in their 
40s or 50s. The deposition of prion protein amyloid was seen throughout peripheral 
organs, including the bowel and peripheral nerves. Neuropathological examination 
during end­stage disease showed the deposition of prion protein in the form of fre­
quent cortical amyloid plaques, cerebral amyloid angiopathy, and tauopathy. A unique 
pattern of abnormal prion protein fragments was seen in brain tissue. Transmis­
sion studies in laboratory mice were negative.
Conclusions
Abnormal forms of prion protein that were found in multiple peripheral tissues 
were associated with diarrhea, autonomic failure, and neuropathy. (Funded by the 
U.K. Medical Research Council and others.)
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The prion diseases are transmissible, fatal, neurodegenerative disorders that may be inherited or acquired or that may occur 
spontaneously as sporadic Creutzfeldt–Jakob dis­
ease.1 The transmissible agent, or prion, is thought 
to comprise misfolded and aggregated forms of 
the normal cell­surface prion protein. Prion prop­
agation is thought to occur by means of seeded 
protein polymerization, a process involving the 
binding and templated misfolding of normal cel­
lular prion protein. Similar processes are increas­
ingly recognized as relevant to other, more com­
mon neurodegenerative diseases. In prion and 
other neurodegenerative disorders, the aggregates 
of misfolded protein in the central nervous sys­
tem are highly heterogeneous, occurring as amy­
loid plaques, more diffuse deposits, and soluble 
species. The inherited prion diseases are auto­
somal dominant disorders caused by mutations 
in the gene encoding prion protein (PRNP).2 These 
disorders have been classified into three over­
lapping neurologic syndromes: the Gerstmann–
Sträussler–Scheinker (GSS) syndrome, fatal fa­
milial insomnia, and familial Creutzfeldt–Jakob 
disease.1
In contrast to the proteins forming abnormal 
deposits in other neurodegenerative diseases, 
prion protein is tethered to the cell membrane 
by a glycosylphosphatidylinositol (GPI) anchor. 
The development of transgenic mice that express 
prion protein lacking the GPI­anchor addition 
site (known as “anchorless” prion protein) has 
been of considerable interest, since these mice 
may propagate infectious prions and abnormal 
prion protein deposits around blood vessels in 
the brain and peripheral tissues, but they show 
highly delayed and variable clinical signs of prion 
disease.3,4 In humans, a premature stop­codon 
mutation also results in abnormal prion protein 
without a GPI anchor, but clinical reports are 
very limited. The PRNP Y145X mutation has been 
described in a single patient with an Alzheimer­
type dementia and prion protein amyloid deposi­
tion in the cerebral vessels,5 the Q160X mutation 
has been described in a small family with demen­
tia,6 and two C­terminal truncation mutations 
have been associated with the GSS syndrome in 
case reports.7 Here we describe the clinical, 
pathological, and molecular characteristics of a 
large kindred with a consistent and novel prion 
disease phenotype that is associated with 
chronic diarrhea and hereditary sensory and 
autonomic neuropathy caused by a novel PRNP 
mutation.
Me thods
Patients
The proband (Patient IV­1) donated his brain to 
the Queen Square Brain Bank for Neurological 
Disorders, London, for research into the cause of 
his family’s neuropathy. Analysis of human tissue 
samples and transmission studies in mice with 
the use of human brain tissue were performed 
with consent from relatives and approval from 
the local research ethics committee. Patients IV­1, 
IV­4, IV­6, V­2, and V­7 provided written informed 
consent.
Immunohistochemical Analysis
After fixation of the tissue, we processed the tis­
sue blocks into paraffin wax with the use of stan­
dard protocols and pretreatment with formic 
acid. Tissue sections with a thickness of 7 μm 
were stained by means of routine methods, in­
cluding hematoxylin and eosin, Luxol fast blue, 
periodic acid–Schiff, Congo red, and thioflavin S. 
Immunohistochemical analysis was performed on 
the basis of a standard avidin–biotin protocol 
with the use of antibodies against prion protein 
(KG9, 3F4, ICSM 35, and Pri­9178), amyloid P com­
ponent, glial fibrillary acidic protein, tau (AT8), 
tau­3R, tau­4R, amyloid­β, neurofilament cock­
tail, TDP­43, CD68, CR3/43, and α­synuclein. (For 
the results of transmission electron microscopy 
and other details, see the Methods section in the 
Supplementary Appendix, available with the full 
text of this article at NEJM.org.)
molecular Genetic and protein studies
We sequenced the entire open reading frame of 
PRNP from genomic DNA using standard tech­
niques. Aliquots of brain homogenate were ana­
lyzed with or without proteinase K digestion and 
with or without phosphotungstic acid precipita­
tion by means of sodium dodecyl sulfate–poly­
acrylamide gel electrophoresis (SDS­PAGE) and 
immunoblotting (see the Methods section in the 
Supplementary Appendix).
Murine Models
Transgenic mice homozygous for a human pri­
on protein 129V transgene array and murine 
prion protein–null alleles (Prnp0/0), designated 
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Tg(HuPrP129V+/+Prnp0/0)­152 mice (129VV Tg152 
mice), or homozygous for a human prion protein 
129M transgene array and murine prion protein–
null alleles, designated Tg(HuPrP129 M+/+Prnp0/0)­35 
mice (129MM Tg35 mice), and inbred FVB/NHsd 
mice were inoculated intracerebrally with brain 
(frontal cortex) obtained from Patient IV­1 (see the 
Methods section in the Supplementary Appendix).
R esult s
Clinical Syndrome
The clinical syndrome was similar in all the pa­
tients and was transmitted as a dominant trait 
(Fig. 1). All the patients for whom clinical details 
were available presented with chronic diarrhea, 
with onset when they were in their 30s, followed 
by symptoms and signs of a mixed, predominant­
ly sensory and autonomic neuropathy (Table S1 in 
the Supplementary Appendix). Watery diarrhea 
was reported to occur several times daily and 
nocturnally and was associated with bloating 
and fluctuating weight, leading to diagnoses of 
the irritable bowel syndrome and Crohn’s disease. 
Urinary retention caused by denervation of the 
bladder, which necessitated intermittent self­
catheterization, and impotence were early symp­
toms in two patients. Another early symptomatic 
feature was postural hypotension, which respond­
ed to therapy with mineralocorticoids and non­
pharmacologic supportive measures. In patients 
with moderately advanced disease, weight loss, 
vomiting, and diarrhea were severe, warranting 
the use of parenteral feeding in two patients. This 
treatment stabilized weight and helped relieve 
nausea and reduce diarrhea, benefits that per­
sisted when normal oral nutrition was reintro­
duced several months later. The onset of cogni­
tive problems and seizures occurred when the 
patients were in their 40s or 50s. The average age 
at the time of death was 57 years (range, 40 to 70).
Electrophysiological studies on 11 occasions 
in five patients consistently showed a progressive, 
length­dependent, predominantly sensory, axonal 
polyneuropathy (Table S2 in the Supplementary 
Appendix). Thermal thresholds were markedly 
abnormal in the feet but not in the hands. Motor 
involvement was less severe, with evidence of de­
nervation, especially in distal leg muscles, at ad­
vanced stages. The clinical and electrophysiolog­
ical studies prompted the diagnosis of hereditary 
sensory and autonomic neuropathy, and the find­
ings are reminiscent of familial amyloid poly­
neuropathy.
Formal neuropsychological studies were per­
formed on eight occasions in three patients. The 
most prominent finding was impairment of 
memory and executive function when the pa­
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Figure 1. Pedigree of Family with a PRNP Y163X Mutation Associated with Chronic Diarrhea and Autonomic Failure.
The family pedigree shows that the disease follows a dominant transmission pattern. The solid symbols (squares for 
males and circles for females) indicate family members who were either affected or presumed to be affected; the 
proband is indicated with an arrow. The number below symbols with a slash is the age at death. Affected family mem-
bers in generations II and III were not assessed in this study and were presumed to have been affected on the basis of 
the medical history provided by relatives and information obtained from medical records or death certificates.
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tients were in their 50s. Two of the markedly 
affected patients (Patients IV­4 and IV­6) showed 
phonologic language impairment. Magnetic reso­
nance imaging (MRI) of the brain showed gen­
eralized volume loss in the supratentorial com­
partment in one patient with advanced disease 
but was normal in the other patients. Exami­
nation of the cerebrospinal fluid showed an eleva­
tion of total tau (>1200 pg per milliliter; nor­
mal range, 0 to 320) and S100b protein (2.17 ng 
per milli liter; normal value, <0.61), and elevated 
amounts of 14­3­3 protein in one patient.
Cardiac assessments were carried out because 
cardiomyopathy occurs in transgenic mice ex­
pressing anchorless prion protein.9 However, 
there were no indications of cardiac involvement 
in the patients’ medical history or on examina­
tion; electrocardiography in six patients and 
echocardiography in three patients showed no 
abnormalities.
Molecular Genetics
Sequencing of PRNP in DNA samples obtained 
from patients who provided consent showed a nov­
el PRNP Y163X mutation. This mutation was found 
in association with valine at polymorphic prion 
protein residue 129 (c.489C→G, p.Y163X) (Fig. 2). 
The polymorphism at codon 129 of PRNP is com­
mon in the healthy population and is known to 
be a strong susceptibility factor for prion dis­
ease, as well as a disease­modifying factor. 
Three other patients with evidence of the clinical 
syndrome (Patients II­2, III­1, and III­5) were 
deemed to be obligate carriers. No mutations were 
found in 18 unrelated patients in whom heredi­
tary sensory and autonomic neuropathy had been 
diagnosed at the National Hospital for Neurol­
ogy and Neurosurgery, which suggests that prion 
disease is not a common cause of this clinical 
syndrome. We have not seen this mutation in 
evaluations of more than 4000 patients and con­
trols.10
Brain and Peripheral-Organ Disease
We hypothesized that this unusual clinical syn­
drome might be associated with an atypical path­
ological appearance and distribution of abnor­
mal prion protein. We therefore investigated the 
tissues obtained both on autopsy (in Patients IV­1, 
IV­4, and IV­6) and on biopsy (in Patients V­2 
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Figure 2. Novel PRNP Y163X Mutation Linked to Codon 129 Valine.
Known or possibly pathogenic mutations are shown in red above this schematic diagram of the gene encoding prion protein (PRNP). 
Structural features are illustrated in the bar. The codon 129 polymorphism (M129V), a common polymorphism in healthy persons and 
an important modifier of the phenotype of prion disease, is shown in blue. The two red bars indicate the location of the codon 129 poly-
morphism and the Y163X mutation. GPI denotes glycosylphosphatidylinositol anchor.
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and V­7). (Histologic and immunohistochemical 
analyses of samples obtained from Patients IV­1 
and IV­6 are shown in Fig. 3.) Duodenal­biopsy 
samples obtained from Patient IV­6 showed ex­
tensive focal accumulation of prion protein in the 
muscularis mucosae as plaques and more diffuse 
deposits in the lamina propria and submucosa 
(Fig. 3D); similar findings were present in several 
biopsy samples obtained from Patient V­2. Histo­
pathological analysis of multiple internal organs 
obtained on autopsy from Patients IV­4 and IV­6 
showed consistent, widespread, and extensive 
deposition of prion protein amyloid (Table S3 in 
the Supplementary Appendix). 
In brief, granular staining was seen around 
ganglion cells in the dorsal­root ganglia and 
around nerve fibers in multiple peripheral nerves. 
Prion protein immunoreactivity was also con­
spicuous between axons of cranial­nerve roots 
and those of dorsal and ventral roots in the 
spinal cord (Fig. 3C). The peripheral lymphore­
ticular system was involved but showed a pattern 
of disease distinct from that seen in patients with 
variant Creutzfeldt–Jakob disease, with abnormal 
prion protein staining of lymphoid capsules and 
stroma. In the cardiovascular system, extensive 
deposition was seen around cardiac myocytes 
and in the walls of arteries and veins. The depo­
sition of prion protein was also seen in the 
portal tract of the liver, around kidney tubules, 
and in lung alveoli. Although abnormal prion 
protein has been detected in peripheral tissues of 
some patients with sporadic Creutzfeldt–Jakob 
disease with the use of high­sensitivity Western 
blot techniques, abnormal prion protein has not 
been identified on immunohistochemical analy­
sis in such patients.11-13
Histologic examination of neocortical regions 
of brain samples obtained from Patient IV­1 
showed mild spongiosis that was restricted main­
ly to cortical layers 1 and 2; findings in Patients 
IV­4 and IV­6 were similar. Vacuolation of deeper 
cortical laminae, which has been associated with 
some forms of sporadic prion disease, was not a 
prominent feature. We observed widespread pri­
on protein plaques and a substantial amount of 
tau­related disease in the form of neurofibrillary 
tangles and neuropil threads (Fig. 4, and Table S4 
in the Supplementary Appendix) — findings that 
are also seen in some forms of the GSS syn­
drome. Microglia also showed immunoreactivity 
for prion protein (Fig. 4C) whereas neurons and 
astrocytes were unstained. Focal prion protein 
immunoreactivity in the walls of capillaries, of­
ten extending into surrounding neuropil, was 
most prominent in subcortical regions. The 
presence of protein deposits with amyloid con­
formation was confirmed with the use of the 
periodic acid–Schiff technique (Fig. 4A, inset), 
which showed immunoreactivity for serum am­
yloid P component (Fig. 4D). Ultrastructural 
examination of neocortex confirmed the pres­
ence of amyloid with the detection of small 
unicentric plaques composed of fibrils radiating 
Figure 3 (facing page). Histologic and Immunohisto-
chemical Analyses of Spinal Cord and Peripheral Tissue 
Obtained from Patients IV-1 and IV-6.
Histologic examination of the spinal cord and periph-
eral tissues obtained from family members was per-
formed to clarify the distribution of deposits of prion 
protein and to determine whether this finding might 
shed light on the clinical findings. The findings were 
very similar for Patient IV-1 (Panels A, B, and C) and 
Patient IV-6 (Panels D through J). In the spinal cord, 
myelinated axonal loss in the dorsal columns was shown 
by a marked reduction in staining of myelin (Panel A, 
arrow). Immunohistochemical analysis showed deposi-
tion of prion protein in the gray matter of the spinal 
cord, which was largely confined to vessel walls (Panel B, 
arrow) and the immediately adjacent neuropil (arrow-
head). In the dorsal roots, there was abundant depo-
sition of prion protein between nerve fibers (Panel C, 
arrow) and in the walls of blood vessels (arrowhead). 
Widespread deposition of prion protein was found in 
the peripheral nervous system and in systemic organs 
in Patient IV-6. Punctate deposits were found in the 
lamina propria and muscularis mucosae of the duode-
num in a biopsy specimen (Panel D, arrows). In post-
mortem samples, the colon showed similar punctate 
staining of the lamina propria and muscularis mucosae 
(Panel E, arrows) in addition to staining at the periph-
ery of lymphoid aggregates (arrowhead). In the spleen 
(Panel F) and a mesenteric lymph node (Panel G), sim-
ilar staining was seen at the margins of follicles (arrows), 
but follicular dendritic cells were unstained, a finding 
that contrasts with findings in samples obtained from 
patients with variant Creutzfeldt–Jakob disease. There 
was pronounced deposition of prion protein around 
ganglion cells in a dorsal-root ganglion (Panel H, arrow) 
and around nerve fibers in peripheral nerves (Panel I, 
median nerve, arrow). In the lung, punctate deposition 
of prion protein was observed in the alveolar walls 
(Panel J, arrow). The scale bar (shown only in Panel A) 
represents 1.9 mm in Panel A, 25 μm in Panels B, C, 
D, H, and J, 100 μm in Panels E and F, and 50 μm in 
Panel G. Staining was performed with the use of Luxol 
fast blue in Panel A, anti–prion protein monoclonal an-
tibody 3F4 in Panels B and C, and anti–prion protein 
monoclonal antibody ICSM 35 in Panels D through J.
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at the periphery (Fig. 4L). To determine whether 
nonmutant prion protein was recruited into de­
posits, immunohistochemical staining with the 
use of an antibody against the C­terminal of prion 
protein (Pri­917, epitope 216–221) was per­
formed.8 This showed a pattern of staining that 
was similar to that seen with the three other 
prion protein antibodies used in the study (Fig. 
4K), although molecular and transmission studies 
did not suggest that nonmutant prion protein is a 
participant in the disease process.
Immunoblotting
Abnormal prion protein in prion disease may be 
studied by means of Western blot analysis after 
partial digestion of the protein with proteases, 
revealing a diversity of fragment sizes and glyco­
sylation patterns that may correlate with clinical 
features.14 We performed these molecular stud­
ies to compare abnormal prion protein in this 
condition with abnormal prion protein seen in 
other prion diseases.
We analyzed 10% brain homogenate (weight 
per volume) prepared from frontal­cortex samples 
obtained from Patients IV­1 and IV­6 before or 
after digestion with proteinase K.15 After diges­
tion, Y163X brain homogenate showed a ladder 
of protease­resistant fragments reactive to anti–
prion protein monoclonal antibody 3F4, with ap­
parent molecular masses ranging from approxi­
mately 10 kDa to more than 100 kDa (Fig. 5A 
and 5B).15 This pattern of disease­related prion 
protein fragments is highly unusual and con­
trasts markedly with the much more discrete 
patterns of truncated proteinase K–resistant prion 
protein fragments that are seen in other prion 
diseases.16-20 Prion protein amino acids 23 to 
162 have a molecular mass of approximately 14.6 
kDa and lack the sites for known post­transla­
tional modification of prion protein by either 
N­glycosylation or the addition of a GPI anchor. 
The presence of proteinase K–resistant species 
of prion protein with apparent molecular masses 
much greater than expected for full­length, digly­
cosylated, nonmutant prion protein suggests that 
prion protein encoded by PRNP Y163X may be 
forming stable sodium dodecyl sulfate–resistant 
oligomers.5
Absence of Transmission to Mice
We performed studies using patients’ brain tis­
sue to determine whether prion infection could 
be transmitted to mice. None of the 24 mice 
from three lines showed any clinical signs of 
prion disease up to 600 days after inoculation, 
Figure 4 (facing page). Neuropathological Analyses  
of Brain Tissue Obtained from Patient IV-1.
Detailed neuropathological examination of the brain 
was performed to establish the key histologic features 
and distribution of deposits of prion protein. Shown 
here are samples obtained from Patient IV-1, in whom 
features were very similar to those in Patients IV-4 and 
Patient IV-6. In the neocortex, small, round eosinophil-
ic structures were seen in the neuropil (Panel A, arrow); 
these structures are stained with Schiff’s reagent (inset). 
Immunohistochemical staining for prion protein revealed 
numerous dense deposits scattered in the cortical neu-
ropil (Panel B, arrows), although neurons and astrocytes 
were unstained. Prion protein immunoreactive structures 
with the morphologic appearance of activated microglia 
(Panel B, arrowhead) were also present in the cortex, 
and the presence of activated microglia was confirmed 
by means of immunohistochemical staining for CR3/43 
(Panel C, arrow, with magnification in inset). Cortical 
deposits were also strongly immunoreactive for amy-
loid P component (Panel D, arrow). Tau immunohisto-
chemical analysis revealed abundant cortical tau disease 
in the form of neurofibrillary tangles (Panel E, arrow, 
with magnification in inset), neuropil threads, and small 
numbers of abnormal neurites (arrowhead). Neuro-
fibrillary tangles were composed of a mixture of three-
repeat tau isoforms (Panel F) and four-repeat tau 
 isoforms (Panel G), indicating tau disease with a bio-
chemical composition similar to that found in Alzheimer’s 
disease. In the cerebellum, there was abundant deposi-
tion of prion protein in the molecular layer (Panel H, 
arrows), where it was predominantly localized in the 
walls of small blood vessels extending into the adjacent 
neuropil (Panel I) and was strongly immunoreactive 
for amyloid P component (Panel J). The presence of 
nonmutant prion protein in deposits was shown with 
the use of a C-terminal–specific antibody, Pri-917 (Pan-
el K). Ultrastructural analysis confirmed the presence 
of cortical amyloid plaques (Panel L, with magnifica-
tion shown in inset). Frontal cortex is shown in Panels 
A, B, C, and E; temporal cortex in Panels D and L; su-
biculum in Panels F and G; and cerebellum in Panels H 
through K. The scale bar (shown only in Panel A) repre-
sents 25 μm in Panels A, B, D, I, J, and K and the in-
sets in Panels C and E and 10 μm in the inset in Panel A; 
50 μm in Panels C, E, F, and G; 260 μm in Panel H; and 
0.7 μm in Panel L and 290 nm in the inset. Staining was 
performed with the use of hematoxylin and eosin in 
Panel A, with periodic acid–Schiff in the inset; ICSM 35 
in Panels B, H, and I; CR3/43 in Panel C, including the 
inset; amyloid P component in Panels D and J; tau im-
munohis tochemical analysis in Panel E; three-repeat tau 
immunohistochemical analysis in Panel F; four-repeat tau 
immunohistochemical analysis in Panel G; and antibody 
Pri-917 in Panel K. The image in Panel L and its inset are 
electron micrographs, so no antibody was used.
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when the experiment was terminated. We also 
analyzed brain samples for subclinical infection 
but observed no proteinase K–resistant prion pro­
tein on Western blot analysis or abnormal depo­
sition of prion protein on immunohistochemical 
analysis.
Discussion
We describe a novel clinical and pathological 
phenotype associated with a Y163X mutation in 
PRNP, a disorder that is of particular interest for 
several reasons. The phenotype is distinct from 
other prion diseases in that it is associated with 
a non­neurologic presentation, the widespread 
deposition of prion protein amyloid in systemic 
organs, and slow disease progression. These find­
ings highlight the possibility that there are pe­
ripheral abnormalities in other brain diseases 
associated with protein misfolding. Since the 
predominant symptoms are peripheral, patients 
often are referred initially to a gastroenterologist 
and undergo gastrointestinal endoscopy and bi­
opsy, before a neurologic opinion is sought; 
thus, the condition is a challenging one to diag­
nose. The unusually long and distinct clinical 
syndrome raises interesting mechanistic issues 
with respect to the role of the GPI anchor in prion 
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Figure 5. High-Sensitivity Immunoblot Analyses of Frontal Cortex Obtained from Patients IV-1 and IV-6.
High-sensitivity immunoblot analyses of prion protein were performed in frontal cortex obtained from Patients IV-1 
and IV-6, both of whom had the PRNP Y163X mutation, to characterize protease-resistant prion protein as com-
pared with known variation in prion disease. Panels A and B show 10 mm3 of 10% frontal cortex homogenates (weight 
to volume) prepared from normal human brain, sporadic Creutzfeldt–Jakob disease brain (sCJD) (PRNP codon 129MM 
with type 2 abnormal prion protein; London classification16), and brain tissue from Patient IV-1 (Panel A) and Pa-
tient IV-6 (Panel B), analyzed before (−) or after (+) digestion with proteinase K (PK) with the use of anti–prion pro-
tein monoclonal antibody 3F4. In the sCJD sample, three PK-resistant immunoreactive bands are seen, representing 
the dif ferent glycosylation states of prion protein with an N-terminal truncation. Because the smallest fragment of 
prion protein that was detected in PK-digested brain homogenate obtained from Patients IV-1 and IV-6 has an ap-
parent molecular mass of approximately 10 kDa, it would appear that prion protein 23-162 is truncated by the prote-
ase. To investigate this further, phosphotungstic acid was used to precipitate disease-related prion protein from de-
tergent-solubilized brain homogenate.15 The pattern of PK-resistant fragments was then reanalyzed with the use of 
different anti–prion protein monoclonal antibodies. Panel C shows PK-digested phosphotungstic acid pellets de-
rived from 33 mm3 of 10% frontal cortex homogenate from Patient IV-1 with the use of anti–prion protein monoclo-
nal  antibodies ICSM 35, ICSM 18, and 3F4 or secondary antibody alone (2°Ab). PK-digested precipitant from the 
sample obtained from Patient IV-1 showed a pattern of PK-resistant fragments of prion protein equivalent to that 
seen after direct PK digestion of brain homogenate, except that the smallest species of prion protein (with an apparent 
molecular mass of approximately 10 kDa) was absent, in contrast to what is seen in Panels A and B. These findings 
suggest that the abnormal prion protein conformer that generates the 10-kDa fragment either is soluble in detergent 
and thus is not recovered by precipitation or becomes sensitive to proteolysis in the presence of detergent. All the 
remaining PK-resistant species of prion protein showed similar immunoreactivity and were reactive with anti–prion pro-
tein mono clonal antibodies ICSM 35 (epitope 93–105 of human prion protein) and 3F4 (epitope 104–113 of human 
prion protein) and nonreactive with anti–prion protein monoclonal antibody ICSM 18 (epitope 142–153 of human pri-
on protein) or secondary antibody alone. The lack of reactivity of all prion protein species with ICSM 18 indicates 
that oligomers are composed of fragments of prion protein that are truncated at the C-terminal by PK. It also indi-
cates that these data exclude the involvement of C-terminal protease-resistant conformers of nonmutant prion pro-
tein that characterize sporadic and acquired CJD and certain forms of inherited prion diseases.
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pathobiology and the toxicity of prion protein 
amyloid.
Prion strains, which are associated with dis­
tinct types of misfolded prion protein, are known 
to be critically important determinants of toxic­
ity and pathological targeting.21 The truncation 
mutation may result in misfolded prion protein 
with radically different strain properties. The 
relative contributions to observed strain proper­
ties of nonmutant prion protein, the lack of a 
GPI anchor, a truncation of the protein, and the 
association between the Y163X mutation and the 
presence of valine at polymorphic residue 129 are 
unclear. These issues might be further addressed 
by the generation of transgenic mice that express 
human prion protein with the Y163X mutation.
Two transgenic mouse models have been re­
ported that have homozygous expression of full­
length prion protein lacking the GPI anchor 
(“anchorless prion protein”). In both models, 
there are vascular and perivascular deposits of 
prion protein that are similar in appearance to 
those in the brains of humans who have inherited 
prion diseases with PRNP stop­codon muta­
tions.3,4 This finding suggests that the cerebro­
vascular phenotype associated with the deposi­
tion of prion protein may relate to the loss of the 
GPI anchor alone, rather than C­terminal trun­
cation of prion protein. One model in trans­
genic mice showed cardiac defects on testing 
but no overt clinical signs,3 whereas a spontane­
ous and transmissible neurodegenerative disease 
developed in a second model.4 After one of these 
models was infected with prions, extraneural de­
position of abnormal prion protein and of infec­
tious prions was seen in peripheral tissues.9,22 
These observations in transgenic mice have paral­
lels with the patients we describe, and it is pos­
sible that poor ascertainment of diarrhea and 
autonomic dysfunction in mice explains the ap­
parent discrepancy in clinical presentation. A fur­
ther distinction is that the transgenic models 
have minimal brain parenchymal deposits of 
prion protein, whereas parenchymal prion pro­
tein amyloid plaques are prominent in patients 
with the Y163X mutation (Fig. 4A, 4B, and 4D).
Autonomic failure and peripheral neuropathy 
are not major clinical features in the recognized 
inherited prion diseases. Dysautonomia has been 
reported in the rapidly progressive fatal familial 
insomnia,23 which is classically caused by a mu­
tation at codon 17824 in association with methio­
nine at polymorphic residue 129. However, pe­
ripheral neuropathy is not a feature of fatal 
familial insomnia.25,26 Inherited prion disease 
associated with the Y163X mutation is consis­
tently associated with autonomic failure, charac­
terized by severe parasympathetic and sympa­
thetic dysfunction. It is likely that the cause of 
autonomic failure is predominantly peripheral, 
as suggested by the clinical and electrophysio­
logical evidence and by evidence of pathologic 
features in the peripheral nervous system. Diar­
rhea in these patients has multiple potential 
causes and may be caused by autonomic dener­
vation of the bowel; alternatively, abnormal prion 
protein may have direct toxic effects on the 
mucosa causing malabsorption, bacterial over­
growth, or gastroparesis, as described in famil­
ial amyloid polyneuropathy.27
Presentation with diarrhea led to invasive in­
vestigations or surgery in several patients, with 
concomitant potential for iatrogenic transmis­
sion of prions from the gut through contamina­
tion of medical or surgical instruments.28 It is 
reassuring, however, that murine studies did not 
show experimental transmissibility, although this 
finding does not completely rule out the pres­
ence of potentially infectious human prions. Al­
though nonmutant prion protein was detected in 
the protein deposits in multiple tissues, Western 
blotting showed that the protein was not protease­
resistant. PRNP analysis should be considered in 
the investigation of unexplained chronic diarrhea 
associated with a neuropathy or an unexplained 
syndrome similar to familial amyloid polyneu­
ropathy. The prevalence of systemic amyloidosis 
associated with prion protein is probably low but 
might be better characterized with more wide­
spread testing of PRNP and histologic examina­
tion for prion protein in biopsy samples.
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